瑞舒伐他汀联合替罗非班治疗对急性缺血性脑卒中患者血清炎症因子、HIF-1α、FGF4、VEGF水平的影响  

Effect of rosuvastatin combined with tirofiban on serum inflammatory factors, HIF-1α, FGF4 and VEGF levels in patients with acute ischemic stroke

作　　者：黎宗宝 唐林[2] 白瑞娜[3] LI Zong-bao;TANG Lin;BAI Rui-na(Emergency Centre,Hainan Affiliated Hospital of Hainan Medical University,Haikou 570311,Hainan,China;Department of Traditional Chinese Medicine,Hainan General Hospital,Hainan Affiliated Hospital of Hainan Medical University,Haikou 570311,Hainan,China;Department of Cardiovascular Medicine,Xiyuan Hospital of China Academy of Chinese Medical Science,Beijing 100091,China)

机构地区：[1]海南省人民医院/海南医学院附属海南医院急救中心,海南省海口市570311 [2]海南省人民医院/海南医学院附属海南医院中医科,海南省海口市570311 [3]中国中医科学院西苑医院心血管内科,北京市100091

出　　处：《广西医学》2022年第14期1565-1568,1573,共5页Guangxi Medical Journal

基　　金：国家自然科学基金(81603489)。

摘　　要：目的 探讨瑞舒伐他汀联合替罗非班治疗对急性缺血性脑卒中患者血清炎症因子、低氧诱导因子1α(HIF-1α)、成纤维细胞生长因子4(FGF4)、血管内皮生长因子(VEGF)水平的影响。方法 选择91例急性缺血性脑卒中患者作为研究对象,将其随机分为单药组(n=45)和联合组(n=46),单药组给予替罗非班治疗,联合组给予瑞舒伐他汀联合替罗非班治疗。比较两组患者治疗前、治疗20 d后血清HIF-1α、FGF4、VEGF、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)水平,以及美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数。评估治疗后两组的临床疗效及不良反应发生情况。结果 治疗后,两组患者血清HIF-1α、FGF4、VEGF、TNF-α、hs-CRP水平及NIHSS评分均较治疗前降低,且联合组以上指标均优于单药组;两组Barthel指数较治疗前升高,且联合组的Barthel指数高于单药组(均P<0.05)。联合组临床总有效率高于单药组(P<0.05),两组患者不良反应总发生率差异无统计学意义(P>0.05)。结论 与替罗非班单独治疗相比,瑞舒伐他汀联合替罗非班治疗急性缺血性脑卒中患者可以更好地降低患者机体细胞因子和炎症因子水平,安全高效。Objective To explore the effect of rosuvastatin combined with tirofiban on serum inflammatory factors, hypoxia inducible factor 1α(HIF-1α), fibroblast growth factor 4(FGF4), vascular endothelial growth factor(VEGF) levels in patients with acute ischemic stroke.Methods A total of 91 patients with acute ischemic stroke were selected as the research subjects, and they were randomly assigned to single drug group(n=45) or combination group(n=46). The single drug group was treated with tirofiban, while the combination group was treated with rosuvastatin combined with tirofiban. The pre-and 20-day post-treatment serum HIF-1α, FGF4, VEGF, tumor necrosis factor α(TNF-α), high-sensitivity C-reactive protein(hs-CRP) levels, as well as the National Institutes of Health Stroke Scale(NIHSS) score, and Barthel index were compared between the two groups. The post-treatment clinical efficacy and the occurrence of adverse reactions were evaluated in both groups.Results After treatment, as compared with before treatment, the levels of serum HIF-1α, FGF4, VEGF, TNF-α, hs-CRP, and NIHSS score were decreased in both groups, and the aforesaid indices of the combination group were superior to those of the single drug group;furthermore, the Barthel index was increased in both groups, and the index of the combination group was higher than that of the single drug group(all P<0.05). The total clinical effective rate in the combination group was higher than that in the single drug group(P<0.05). There was no statistically significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Compared with tirofiban for treatment alone, rosuvastatin combined with tirofiban for treating patients with acute ischemic stroke can preferably decrease the levels of body cytokines and inflammatory factors, exerting higher safety and efficiency.

关 键 词：急性缺血性脑卒中 瑞舒伐他汀 替罗非班 低氧诱导因子1Α 成纤维细胞生长因子4 血管内皮生长因子 炎症因子 

分 类 号：R743.3[医药卫生—神经病学与精神病学]